Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers

References

• Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971–4
   PubMed Web of Science ®Google Scholar
• Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Safety 1998;18:43–56
   PubMed Web of Science ®Google Scholar
• Cohen L, DeMoor C, Eisenberg P et al. Delayed chemotherapy-induced nausea and vomiting (CINV) remains a problem and significantly interferes with daily function (DF) in patients receiving emetogenic chemotherapy (CT) in the United States. Proc Am Soc Clin Oncol 2003;22:739 [Abstract 2972]
   Google Scholar
• Grunberg SM, Deuson R, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261–8
   PubMed Web of Science ®Google Scholar
• Aloxi® [package insert]. Lugano, Switzerland: Helsinn Healthcare SA; 2003
   Google Scholar
• Zofran® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004
   Google Scholar
• Kytril® [package insert]. Nutley, NJ: Roche Laboratories; 2002
   Google Scholar
• Anzemet® [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals; 2003
   Google Scholar
• Wong EH, Clark R, Leung E, et al. The interaction of RS 25259197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. B J Pharmacol 1995;114:851–9
   PubMed Web of Science ®Google Scholar
• Miller RC, Galvan M, Gittos MW Vangiersbergen PLM, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993;28: 87–93
   Google Scholar
• Aapro M, Bertoli L, Lordick F, et al. Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy- induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Supp Care Cancer 2003;11:391 [Abstract A–17]
   Google Scholar
• Eisenberg P Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT receptor antagonist. Cancer 2003;98:2473–82
   PubMedGoogle Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7
   Google Scholar
• Stoltz R, Cyong J-C, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol 2004;44: 520–31
   Google Scholar
• Eisenberg P MacKintosh FR, Ritch P Cornett PA, Macciocchi A. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based, chemotherapy: a dose-ranging, clinical study. Ann Oncol 2004;15:330–37
   PubMed Web of Science ®Google Scholar
• Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism, and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004;25:329–37
   PubMed Web of Science ®Google Scholar
• Emend® [package insert]. Whitehouse Station, NJ: Merck & Co; 2003
   Google Scholar
• Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407–19
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies – Study Design, Data Analyses, and Recommendations for Dosing and Labeling. Washington, DC: US Department of Health and Human Services, 1999
   Google Scholar
• McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17–24
   PubMed Web of Science ®Google Scholar
• Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002;8:405–14
   PubMed Web of Science ®Google Scholar
• McCrea J, Majumdar A, Busillo J, et al. Lack of effect of aprepitant on the pharmacokinetics of ondansetron. Clin Pharmacol Ther 2003;73:PI–18
   Google Scholar
• Petty KJ, Majumdar A, Orlowski LH, et al. Lack of effect of aprepitant on the pharmacokinetics of granisetron. Clin Pharmacol Ther 2003;73:PI–19
   Google Scholar